Neurokinin-1 Receptor Directly Mediates Glioma Cell Migration by Up-regulation of Matrix Metalloproteinase-2 (MMP-2) and Membrane Type 1-matrix Metalloproteinase (MT1-MMP)

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Nov 21

PMID 23166329

Citations 18

Authors

Lingyun Mou

Yawei Kang

Ying Zhou

Qian Zeng

Hongjing Song

Rui Wang

Affiliations

Soon will be listed here.

Abstract

Neurokinin-1 receptor (NK1R) occurs naturally on human glioblastomas. Its activation mediates glioma cell proliferation. However, it is unknown whether NK1R is directly involved in tumor cell migration. In this study, we found human hemokinin-1 (hHK-1), via NK1R, dose-dependently promoted the migration of U-251 and U-87 cells. In addition, we showed that hHK-1 enhanced the activity of MMP-2 and the expression of MMP-2 and MT1-matrix metalloproteinase (MMP), which were responsible for cell migration, because neutralizing the MMPs with antibodies decreased cell migration. The involved mechanisms were then investigated. In U-251, hHK-1 induced significant calcium efflux; phospholipase C inhibitor U-73122 reduced the calcium mobilization, the up-regulation of MMP-2 and MT1-MMP, and the cell migration induced by hHK-1, which meant the migration effect of NK1R was mainly mediated through the G(q)-PLC pathway. We further demonstrated that hHK-1 boosted rapid phosphorylation of ERK, JNK, and Akt; inhibition of ERK and Akt effectively reduced MMP-2 induction by hHK-1. Meanwhile, inhibition of ERK, JNK, and Akt reduced the MT1-MMP induction. hHK-1 stimulated significant phosphorylation of p65 and c-JUN in U-251. Reporter gene assays indicated hHK-1 enhanced both AP-1 and NF-κB activity; inhibition of ERK, JNK, and Akt dose-dependently suppressed the NF-κB activity; only the inhibition of ERK significantly suppressed the AP-1 activity. Treatment with specific inhibitors for AP-1 or NF-κB strongly blocked the MMP up-regulation by hHK-1. Taken together, our data suggested NK1R was a potential regulator of human glioma cell migration by the up-regulation of MMP-2 and MT1-MMP.

Citing Articles

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.

Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.

Cao X, Yang Y, Zhou W, Wang Y, Wang X, Ge X BMC Cancer. 2023; 23(1):471.

PMID: 37221457 PMC: 10204192. DOI: 10.1186/s12885-023-10954-8.

Neurotransmitters: Potential Targets in Glioblastoma.

Huang Q, Chen L, Liang J, Huang Q, Sun H Cancers (Basel). 2022; 14(16).

PMID: 36010960 PMC: 9406056. DOI: 10.3390/cancers14163970.

The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.

Momen Razmgah M, Ghahremanloo A, Javid H, Alalikhan A, Afshari A, Hashemy S Mol Biol Rep. 2022; 49(10):9307-9314.

PMID: 35960409 DOI: 10.1007/s11033-022-07771-w.

The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.

Munoz M, Arguelles S, Rosso M, Medina R, Covenas R, Ayala A Biomed Res Int. 2022; 2022:6291504.

PMID: 35434136 PMC: 9006081. DOI: 10.1155/2022/6291504.

References

Lohi J, Lehti K, Valtanen H, Parks W, Keski-Oja J . Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene. 2000; 242(1-2):75-86. DOI: 10.1016/s0378-1119(99)00549-1. View

Guha A, Mukherjee J . Advances in the biology of astrocytomas. Curr Opin Neurol. 2004; 17(6):655-62. DOI: 10.1097/00019052-200412000-00004. View

Munoz M, Rosso M, Covenas R . The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets. 2011; 12(6):909-21. DOI: 10.2174/138945011795528796. View

Mou L, Xing Y, Kong Z, Zhou Y, Chen Z, Wang R . The N-terminal domain of human hemokinin-1 influences functional selectivity property for tachykinin receptor neurokinin-1. Biochem Pharmacol. 2010; 81(5):661-8. DOI: 10.1016/j.bcp.2010.12.007. View

Rao J . Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003; 3(7):489-501. DOI: 10.1038/nrc1121. View

Schratzberger P, Reinisch N, Prodinger W, Kahler C, Sitte B, Bellmann R . Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. J Immunol. 1997; 158(8):3895-901. View

Meshki J, Douglas S, Hu M, Leeman S, Tuluc F . Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PLoS One. 2011; 6(9):e25332. PMC: 3179504. DOI: 10.1371/journal.pone.0025332. View

Kwiatkowska A, Kijewska M, Lipko M, Hibner U, Kaminska B . Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta. 2011; 1813(5):655-67. DOI: 10.1016/j.bbamcr.2011.01.020. View

Meshki J, Douglas S, Lai J, Schwartz L, Kilpatrick L, Tuluc F . Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem. 2009; 284(14):9280-9. PMC: 2666580. DOI: 10.1074/jbc.M808825200. View

10.

Nakada M, Nakada S, Demuth T, Tran N, Hoelzinger D, Berens M . Molecular targets of glioma invasion. Cell Mol Life Sci. 2007; 64(4):458-78. PMC: 11138430. DOI: 10.1007/s00018-007-6342-5. View

11.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

12.

Clark I, Swingler T, Sampieri C, Edwards D . The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008; 40(6-7):1362-78. DOI: 10.1016/j.biocel.2007.12.006. View

13.

Palma C . Tachykinins and their receptors in human malignancies. Curr Drug Targets. 2006; 7(8):1043-52. DOI: 10.2174/138945006778019282. View

14.

Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi C . Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990; 40(2):264-78. DOI: 10.1016/0026-2862(90)90024-l. View

15.

Page N, Bell N, Gardiner S, Manyonda I, Brayley K, Strange P . Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A. 2003; 100(10):6245-50. PMC: 156357. DOI: 10.1073/pnas.0931458100. View

16.

Molina J, Hayashi Y, Stephens C, Georgescu M . Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia. 2010; 12(6):453-63. PMC: 2887086. DOI: 10.1593/neo.10126. View

17.

Janelsins B, Mathers A, Tkacheva O, Erdos G, Shufesky W, Morelli A . Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood. 2008; 113(13):3017-26. PMC: 2662645. DOI: 10.1182/blood-2008-06-163121. View

18.

Lieb K, Fiebich B, Berger M, Bauer J, Schulze-Osthoff K . The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol. 1997; 159(10):4952-8. View

19.

Sakai A, Takasu K, Sawada M, Suzuki H . Hemokinin-1 gene expression is upregulated in microglia activated by lipopolysaccharide through NF-κB and p38 MAPK signaling pathways. PLoS One. 2012; 7(2):e32268. PMC: 3288086. DOI: 10.1371/journal.pone.0032268. View

20.

Koon H, Zhao D, Zhan Y, Moyer M, Pothoulakis C . Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci U S A. 2007; 104(6):2013-8. PMC: 1794289. DOI: 10.1073/pnas.0610664104. View